Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis
Annals of Oncology, 06/15/2012
Tarantini L et al. – In clinical practice, 32% of human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (HER2+EBC) patients treated with aTrastC are ‘over–60’. These patients have an increased cardiovascular risk profile and develop aTrastC cardiotoxicity commonly.